Ambisome (Fovea Pharmaceuticals)

Ambisome is a liposomal formulation of the polyene antifungal amphotericin B, designed to improve the therapeutic index of the drug by reducing nephrotoxicity while maintaining broad-spectrum antifungal activity. The mechanism of action involves the binding of amphotericin B to ergosterol, a critical component of fungal cell membranes. This binding leads to the formation of transmembrane pores that cause the lethal leakage of intracellular ions, such as potassium, and other essential cellular components, ultimately resulting in fungal cell death. In the clinical context associated with Fovea, Ambisome was evaluated in a Phase 4 study as a preemptive treatment (administered at 10 mg/kg/week) for intensive care patients with sepsis and rising Candida colonization to prevent the development of systemic fungal infections.

Brand names

Ambisome

Other names

liposomal amphotericin Bamphotericin B liposomal